Comparing of Cronos Group Inc. (CRON) and Ovid Therapeutics Inc. (NASDAQ:OVID)

We are contrasting Cronos Group Inc. (NASDAQ:CRON) and Ovid Therapeutics Inc. (NASDAQ:OVID) on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cronos Group Inc. N/A 0.00 N/A -0.03 0.00
Ovid Therapeutics Inc. N/A 0.00 52.60M -2.03 0.00

Table 1 demonstrates Cronos Group Inc. and Ovid Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Cronos Group Inc. 0.00% 0% 0%
Ovid Therapeutics Inc. 0.00% 0% 0%

Analyst Recommendations

The next table highlights the given recommendations and ratings for Cronos Group Inc. and Ovid Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cronos Group Inc. 1 1 1 2.33
Ovid Therapeutics Inc. 0 0 0 0.00

Cronos Group Inc.’s upside potential is 18.89% at a $20.33 average target price.

Insider & Institutional Ownership

Roughly 9.35% of Cronos Group Inc. shares are owned by institutional investors while 25.8% of Ovid Therapeutics Inc. are owned by institutional investors. Insiders owned 48.28% of Cronos Group Inc. shares. On the other hand, insiders owned about 12.1% of Ovid Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cronos Group Inc. -2.01% -3.99% -25.92% 77.19% 130.95% 45.81%
Ovid Therapeutics Inc. -5.43% -4.92% -29.55% -66.21% -80.58% -28.1%

For the past year Cronos Group Inc. has 45.81% stronger performance while Ovid Therapeutics Inc. has -28.1% weaker performance.


Cronos Group Inc. beats on 4 of the 5 factors Ovid Therapeutics Inc.

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome. It is also developing OV935, a drug candidate that is in Phase I trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the hospital setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.